The feature in the latest issue of the renowned Nature Research publication gives an insightful overview of EsoCap’s company profile and the current development stage of their novel platform technology for the world’s first local treatment of the esophagus. The article explains what makes the innovative application technology so unique.
“The advanced phase of development is just the start of the story”, said Isabelle Racamier, EsoCap CEO. “EsoCap is building a business strategy towards partnering. The EsoCap platform will be valuable for biopharmaceutical companies already working in gastroenterology, immunology or oncology, as well as for contract manufacturers.”